$ACRX Part 1 of 2, relentless shorts stealing shares: It took AVNR about 3 years from FDA approval to start selling their drug... ACRX's XERAVA launched a few months earlier than DSUVIA, is now seeing 45% revenue growth over the prior quarter (Q4 vs. Q3)… ACRX CEO said, DSUVIA is not far behind... AcelRx's has 10 plus years *PATENTS* on all its drugs, now including the HUGE potential blockbuster superbug drug XERAVA... HEADS up comparison, AVNR to ACRX, AVRN shorts were RELENTLESS (like ACRX shorts, including Credit Suisse) saying AVNR was worth $1.00, note a few years later AVNR was purchased for $17 per share or $3.5 billion dollars: "Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff" Avanir's drug was called the WORST drug launch in history by the Shorts, notice who this misleading author is, he is now in JAIL:
  • 1
  • 2